Working… Menu

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice (NETways)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03895463
Recruitment Status : Withdrawn (Reassessment of study feasibility)
First Posted : March 29, 2019
Last Update Posted : August 6, 2019
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : March 26, 2023
Estimated Study Completion Date : March 26, 2023